C-FDMWLoyal
canine aging therapeutics, metabolic dysfunction
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-FDMW
C-FDMWC-FDMWcanine aging therapeutics, metabolic dysfunction
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Loyal canine aging therapeutics, metabolic dysfunction
Loyal is developing drugs intended to help dogs live longer and stay healthier as they age. Its approach targets underlying processes that lead to age-associated disease and disability. The company's lead drug, LOY-002, targets metabolic dysfunction in senior dogs and has completed two of three major FDA conditional approval requirements, according to the supplied page text.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Loyal — Far from goals · Lower middle. Derived deterministically from 11 extracted project(s). Most-advanced status: exploratory. Band: far. Modifiers: +5 depth (7 programs at exploratory).…
Source: Deterministic